Overview

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Status:
Terminated
Trial end date:
2019-01-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.
Phase:
Phase 2
Details
Lead Sponsor:
Elevation Oncology
Merrimack Pharmaceuticals
Collaborator:
Merrimack Pharmaceuticals
Treatments:
Docetaxel
Pemetrexed